TFFP Stock Overview
A clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TFF Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.37 |
| 52 Week High | US$11.00 |
| 52 Week Low | US$0.27 |
| Beta | 1.32 |
| 11 Month Change | -83.81% |
| 3 Month Change | -85.95% |
| 1 Year Change | -95.00% |
| 33 Year Change | -99.80% |
| 5 Year Change | -99.71% |
| Change since IPO | -99.71% |
Recent News & Updates
Recent updates
Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?
Apr 10
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?
Sep 27TFF Pharma: The Potential Is Still Very Much Present
Aug 29TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways
Aug 09TFF Pharmaceuticals expands R&D operations with new Austin facility
Jul 14TFF Pharmaceuticals: A Highly Attractive Basket Of Options
May 23We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully
May 17Shareholder Returns
| TFFP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -77.8% | -3.8% | -1.0% |
| 1Y | -95.0% | 9.8% | 30.3% |
Return vs Industry: TFFP underperformed the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: TFFP underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| TFFP volatility | |
|---|---|
| TFFP Average Weekly Movement | 28.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TFFP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TFFP's weekly volatility has increased from 20% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 19 | Craig Jalbert | tffpharma.com |
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
TFF Pharmaceuticals, Inc. Fundamentals Summary
| TFFP fundamental statistics | |
|---|---|
| Market cap | US$1.37m |
| Earnings (TTM) | -US$19.39m |
| Revenue (TTM) | US$1.20m |
1.1x
P/S Ratio-0.1x
P/E RatioIs TFFP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TFFP income statement (TTM) | |
|---|---|
| Revenue | US$1.20m |
| Cost of Revenue | US$11.40m |
| Gross Profit | -US$10.20m |
| Other Expenses | US$9.19m |
| Earnings | -US$19.39m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.59 |
| Gross Margin | -847.92% |
| Net Profit Margin | -1,612.03% |
| Debt/Equity Ratio | 0% |
How did TFFP perform over the long term?
See historical performance and comparison